These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32592467)

  • 1. Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys.
    Dang UJ; Ziemba M; Clemens PR; Hathout Y; Conklin LS; ; Hoffman EP
    Hum Mol Genet; 2020 Aug; 29(15):2481-2495. PubMed ID: 32592467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice.
    Ziemba M; Barkhouse M; Uaesoontrachoon K; Giri M; Hathout Y; Dang UJ; Gordish-Dressman H; Nagaraju K; Hoffman EP
    PLoS One; 2021; 16(2):e0246507. PubMed ID: 33617542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.
    Li X; Conklin LS; van den Anker J; Hoffman EP; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2020 Oct; 60(10):1385-1396. PubMed ID: 32434278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
    Dang UJ; Damsker JM; Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans NM; Haberlová J; Straub V; Mengle-Gaw L; Schwartz BD; Harper A; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster RI; Mcmillan HJ; Kuntz N; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez JJ; Nascimento-Osorio A; Niks EH; De Groot IJM; Katsalouli M; Van Den Anker JN; Ward LM; Leinonen M; D'Alessandro AL; Hoffman EP
    Neurology; 2024 Mar; 102(5):e208112. PubMed ID: 38335499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
    Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR;
    Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy.
    Zhang H; Zhu Y; Sun Y; Liang Y; Li Y; Zhang Y; Deng L; Wen X; Zhang C
    Dis Markers; 2015; 2015():141856. PubMed ID: 25852218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
    Janghra N; Morgan JE; Sewry CA; Wilson FX; Davies KE; Muntoni F; Tinsley J
    PLoS One; 2016; 11(3):e0150818. PubMed ID: 26974331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
    Hathout Y; Brody E; Clemens PR; Cripe L; DeLisle RK; Furlong P; Gordish-Dressman H; Hache L; Henricson E; Hoffman EP; Kobayashi YM; Lorts A; Mah JK; McDonald C; Mehler B; Nelson S; Nikrad M; Singer B; Steele F; Sterling D; Sweeney HL; Williams S; Gold L
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7153-8. PubMed ID: 26039989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy.
    Li X; Sabbatini D; Pegoraro E; Bello L; Clemens P; Guglieri M; van den Anker J; Damsker J; McCall J; Dang UJ; Hoffman EP; Jusko WJ
    J Clin Pharmacol; 2024 Sep; 64(9):1130-1140. PubMed ID: 38682893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological effects of givinostat in boys with Duchenne muscular dystrophy.
    Bettica P; Petrini S; D'Oria V; D'Amico A; Catteruccia M; Pane M; Sivo S; Magri F; Brajkovic S; Messina S; Vita GL; Gatti B; Moggio M; Puri PL; Rocchetti M; De Nicolao G; Vita G; Comi GP; Bertini E; Mercuri E
    Neuromuscul Disord; 2016 Oct; 26(10):643-649. PubMed ID: 27566866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.
    Mavroudis PD; van den Anker J; Conklin LS; Damsker JM; Hoffman EP; Nagaraju K; Clemens PR; Jusko WJ
    J Clin Pharmacol; 2019 Jul; 59(7):979-988. PubMed ID: 30742306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
    Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
    J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital PCR quantification of miR-30c and miR-181a as serum biomarkers for Duchenne muscular dystrophy.
    Llano-Diez M; Ortez CI; Gay JA; Álvarez-Cabado L; Jou C; Medina J; Nascimento A; Jimenez-Mallebrera C
    Neuromuscul Disord; 2017 Jan; 27(1):15-23. PubMed ID: 27979502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
    Conklin LS; Damsker JM; Hoffman EP; Jusko WJ; Mavroudis PD; Schwartz BD; Mengle-Gaw LJ; Smith EC; Mah JK; Guglieri M; Nevo Y; Kuntz N; McDonald CM; Tulinius M; Ryan MM; Webster R; Castro D; Finkel RS; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; McCall JM; Hathout Y; Nagaraju K; van den Anker J; Ward LM; Ahmet A; Cornish MR; Clemens PR
    Pharmacol Res; 2018 Oct; 136():140-150. PubMed ID: 30219580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.
    Savino W; Pinto-Mariz F; Mouly V
    Methods Mol Biol; 2018; 1687():219-227. PubMed ID: 29067667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.